Publication date: Jul 05, 2026
Long COVID comprises heterogeneous symptoms that may persist for months to years after acute SARS-CoV-2 infection. While prevalence is well described, less is known about symptom duration and determinants of recovery. We conducted a multicenter longitudinal cohort study across 12 institutions in Korea (December 2022-March 2025), enrolling adults with confirmed infection and uninfected controls. Participants were followed for up to 22 months with repeated assessments of symptoms, vaccination, and comorbidities. Eight common symptoms were analyzed. Time to resolution was estimated using Kaplan-Meier methods and log-normal accelerated failure time models, adjusting for demographic and clinical factors. Results are reported as time ratios (TRs). Among 757 infected participants and 558 controls, respiratory and physical symptoms resolved similarly between groups, whereas systemic and neurological symptoms persisted longer in infected individuals. At one year, 20-25% reported fatigue and 15-20% sleep disturbance versus ∼10% and ∼5% in controls. Infection was associated with ∼50% longer duration of fatigue and sleep disturbance. Individuals aged 40-59 recovered more slowly; other factors showed minimal associations. Persistent long COVID burden is driven by systemic neuro-related symptoms, highlighting the need for targeted, symptom-specific management strategies.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Comorbidities | Accelerated Failure Time |
| December | fatigue |
| Korea | Post-acute COVID-19 syndrome |
| Vaccination | Republic of Korea |
| sleep disorder |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Long COVID |
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| disease | MESH | fatigue |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | sleep disorder |
| disease | MESH | cognitive impairment |
| disease | MESH | obesity |
| disease | MESH | hypertension |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | cancer |
| disease | MESH | cognitive symptoms |
| disease | MESH | cough |
| disease | MESH | rhinorrhea |
| disease | MESH | arthritis |
| drug | DRUGBANK | Isoxaflutole |
| disease | MESH | included |
| disease | MESH | Underweight |
| disease | MESH | SMD |
| drug | DRUGBANK | Ethanol |
| disease | MESH | inflammation |
| disease | MESH | relapse |
| disease | MESH | reinfection |
| disease | MESH | influenza |
| disease | MESH | neurological manifestations |
| disease | MESH | Dis |
| disease | MESH | syndrome |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | MESH | Lam |
| disease | MESH | Neuroinflammation |